Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

Also participating in today's call are Adam Lenkowsky, our Chief Commercialization Officer; and Samit Hirawat, our Chief Medical Officer and Head of Global Drug ... sales of Eliquis were offset ...

Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Bristol Myers Squibb posted Q4 revenue of $12.34B, beating the consensus, with an 8% YoY increase driven by Growth Portfolio and Eliquis ... The arthritis drug Orencia generated sales of $1 ...

The trial enrolled 60 healthy volunteers to compare TAH3311 ODF with the Apixaban tablet (brand name Eliquis®) under the bioequivalence (BE) regulatory framework. Apixaban, a Factor Xa inhibitor ...

The trial enrolled 60 healthy volunteers to compare TAH3311 ODF with the Apixaban tablet (brand name Eliquis®) under the bioequivalence (BE) regulatory framework. Apixaban, a Factor Xa inhibitor, is ...